Onward Medical announces the publication of a one year study showing the benefit of the access sustained to the Arc -X therapy

The study shows significant functional improvements after one year of Arc -X therapy

Improvements have been observed during the one -year treatment period without a plateau

Results demonstrate the importance of sustained access to Arc -X therapy

Eindhoven, Holland, February 25, 2025 (Globe Newswire) – Onward Medical NV (Euronext: ONWD), the medical technology company that creates innovative spinal stimulation therapies to restore the movement, function and independence in people with spinal cord injury (SCI) and other movement disabilities, today announces the publication of results positive from the study Pathfinder2 sponsored by investigators in Neuromodular: technology at neuronal interface.

The Revised Equal Work details the discoveries of a one-year study that shows that Arc-EX therapy.

“The results of Pathfinder2 published today in neuromodulation Demonstrate that people with SCI can get continuous earnings with supported access to Arc -X therapy, “said Dave Marver, CEO Onward Medical.” Congratulations on the Neurokinex team because it has shown Arc -X therapy can help people with SCI functional recovery without a plateau during a one-year treatment period. “

Study, sponsored by the UK, based in the UK Spine researchand driven independently of Neurokinex In his network of community -based rehabilitation centers, he scored 10 participants with chronic cervical or thoracic SCI. Participants have made earnings in the upper body force, trunk control and balance, without any indication of plateau for the therapeutic benefit after a year of treatment. Some participants also improved the lower body movement and improved hand and arm strength, especially in grip and dexterity.*

“Now is the time not to talk about the injury of the spinal cord as incurable and start talking about it as improvised,” said Tara Stewart, President Spinal Research. “This advanced device shows that the function can be restored. With appropriate investments in spinal cord research, we can accelerate progress to significant treatments for paralysis. Science shows promise – what we need now is financing to advance this critical work.”

In addition, 3 participants have improved the classification on the depreciation scale of the Association of Spinal Column (AIS) and 4 have shown changes in their neurological level of injury, including a participant who has passed from the complete to incomplete. These discoveries strengthen the long-term benefits of continuous access to Arc -X therapy and suggest that additional earnings can be obtained with extensive treatment.

“This peer revised publication validates that Arc-Ex-EX therapy.” Most importantly, participants have continued to show improvements over 120 treatment sessions for a period of year, which suggests that there is Additional recovery potential with extended treatment. ”

“I am extremely encouraged by the positive results of the Pathfinder2 study and I think that Arc -X therapy will allow us to offer even greater winnings for people living with a spinal cord injury,” said Harvey Sihota, founder and CEO of Neurokinex. It is not undoubtedly that the technologies to stimulate the spine will take the rehabilitation of the spinal cord injuries and the results at the next level, bringing more significant functional improvements, which provide people with greater independence. “

In December 2024, the ARC-AX Award system^® It was approved by the US FDA for use in the clinic settings. Home use authorization is anticipated at the end of this year. The company intends to seek CE certification for the commercialization of the Arc -X system in Europe in 2025.

Onward Medical develops a technology pipe, including its implantable Arc-IM system and its Arc-BCI investigation system, an implanted platform that uses an interface brain (BCI) powered by artificial intelligence (AI). To find out more about the commitment to partnership with the SCI community to develop innovative solutions to restore the movement, function and independence after the spinal cord injury, please visit Onwd.com.

To be informed of the company’s technologies, research studies and the availability of therapies in your area. Complete this web form.

About the medical

Onward Medical is a medical technology company that creates therapies to restore the movement, function and independence in people with SCI and other movement disabilities. Building more than a decade of scientific discovery, preclinical research and clinical studies carried out at leading hospitals, rehabilitation clinics and neuroscience laboratories, the company has developed Arc Therapy, which received ten names of discovery devices from the US Food Administration and US drugs (FDA). In addition to the ARC -X system, which is now deleted for commercial sale in the US, the company develops an implantable system called ARCIM with and without an implanted brain-computer interface (BCI).

With headquarters in the Netherlands, the company has a science and engineering center in Switzerland and an American office in Boston, Massachusetts. The company is listed on Euronext Paris, Brussels and Amsterdam (Ticker: ONWD).

For more information, visit Onwd.com and connect with us on LinkedIn and YouTube.

To be informed of the company’s technologies, research studies and the availability of therapies in your area. Complete this web form.

For media investigations:
[email protected]

For investors investigations:
[email protected]

renunciation

Certain statements, beliefs and opinions in this press release are prospective, which reflect the company or, as the case may be, the current expectations and projections of the company directors about future events. By their nature, prospective statements involve several risks, uncertainties and assumptions that could cause real results or events to differ significantly from those expressed or involved by prospective statements. These risks, uncertainties and hypotheses could negatively affect the result and financial effects of the plans and events described here. A multitude of factors, including, but not limited to, delays in regulatory approvals, changes in demand, competition and technology, can determine events, performance or real results to differ significantly from any anticipated development. The prospective statements contained in this press release on previous trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the company expressly declines any obligation or commitment to issue any update or revisions to any prospective statements today these prospective statements are based. Neither the company, nor its counselors or representatives, nor one of its branch companies or officers or employees these persons guarantee that the assumptions underlying these prospective statements are without errors, nor accept any responsibility for future accuracy statements contained in this statement. press or effective appearance of forecast developments. You should not place an unjustified addiction on prospective statements, which only speak from the date of this press release.

*ARC-EX indication for use (USA): The ARC -x system is intended to provide programmed, transcutaneous stimulation of the electric spinal cord, in combination with the functional practice of pregnancy in the clinic to improve the sensation and power of the hands in people aged. Between 18 and 75 years of age with a chronic, non-prrogressive neurological deficit, resulting from an incomplete marrow lesion spines (C2-C8 inclusive).

Other investigation products: All other medical devices and therapies, including Arc-Im and Arc-BCI are investigations and are not available for commercial use.

Commercial brands: one, arc-ex, arc-we, arc-BCI and O-Logo stylized are commercial and registered medical brands. Unauthorized use is strictly forbidden.